Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plamotamab in CD20-Expressing Hematologic Malignancies
NCT02924402Phase 1Completed
- Sponsor
- Xencor
- Start
- Oct 2016
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of Plamotamab in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL) (6 arms), sponsored by Xencor. Primary endpoints: Safety and tolerability as determined by the number of participants with treatment-related adverse events and Maximum tolerated dose (MTD) and/or recommended dose (RD). Started Oct 2016; status: completed.
02
Drugs
Plamotamab
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02924402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924402.